Clinical trials
Cholangiocarcinoma clinical trials
Below are recruiting cholangiocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 190 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06296563RecruitingPhase 2
Testing adebrelimab, apatinib, and HAIC for bile duct cancer
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
Jinan, ShandongAges 18 years+ - NCT07847710RecruitingPhase 2
Combination therapy before and after surgery for early liver cancer
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
Nanjing, JiangsuAges 18–75 - NCT04340986Recruiting
Group study for bile duct or liver cancer patients
This study follows people with bile duct cancer or certain liver cancers to better understand their disease. You might be included if you meet the diagnosis and basic participation requirements.
ParisAges 18 years+ - NCT06298968RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07766187RecruitingPhase 2
Durvalumab and focused ultrasound for liver cancer after chemo
This trial tests combining two treatments: durvalumab (an immunotherapy drug) and histotripsy (a focused ultrasound that breaks down tumor tissue) for people with a type of liver cancer called intrahepatic cholangiocarcinoma. It aims to see if adding histotripsy after initial chemotherapy helps control the cancer better.
Madison, WisconsinAges 18 years+ - NCT07673341RecruitingPhase 2
PET scan to predict response in bile duct cancer
This study tests whether a special PET scan (using [18F]FTT) can predict how well the standard GCD chemotherapy and immunotherapy combination will work for newly diagnosed bile duct cancer. The scan helps doctors see tumor activity before treatment.
Seattle, WashingtonAges 18 years+ - NCT06341764RecruitingPhase 2
Chemo-immunotherapy before surgery for bile duct cancer
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
Naples, ItaliaAges 18 years+ - NCT07640048Recruiting
Adjuvant therapy after surgery for high-risk bile duct cancer
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
BeijingAges 18 years+ - NCT07636824RecruitingPhase 2
Chemotherapy plus radiation after bile duct cancer surgery
This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.
BeijingAges 18–80 - NCT06721286RecruitingPhase 2
Combining immunotherapy with chemotherapy before surgery for bile duct cancer
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07570849RecruitingPhase 2
Chidamide with chemotherapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06746480RecruitingPhase 2
Study of VG161 for advanced bile duct cancer
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07522476RecruitingPhase 2
VG2025 treatment for advanced bile duct cancer
This trial tests a new drug called VG2025 to treat advanced intrahepatic cholangiocarcinoma, a type of cancer that starts in the bile ducts inside the liver. The study aims to see if VG2025 is safe and effective at slowing or stopping this cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06664021RecruitingPhase 2
Tislelizumab and S-1 for recurrent high-risk bile duct cancer
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Fuyang, AnhuiAges 18–75 - NCT06607276RecruitingPhase 2
Adjuvant adebrelimab and capecitabine for high-risk bile duct cancer
This trial is for people with bile duct cancer who have had surgery to remove all visible cancer but are at high risk of it coming back. It tests whether adding two medications — adebrelimab (an immunotherapy) and capecitabine (a chemotherapy pill) — after surgery can help prevent the cancer from returning.
Nanjing, JiangsuAges 18–75 - NCT06718257Recruiting
Chemo with immunotherapy and targeted drugs for bile duct cancer
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
Hangzhou, ZhejiangAges 18 years+ - NCT05532059RecruitingPhase 2
Test lenvatinib, tislelizumab, and chemotherapy for bile duct cancer
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
Hangzhou, ZhejiangAges 18–85 - NCT05823311RecruitingPhase 3
Test lenvatinib and immunotherapy plus chemo for bile duct cancer
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
Hangzhou, ZhejiangAges 18–75 - NCT04954781RecruitingPhase 2
Chemo plus immunotherapy for advanced bile duct liver cancer
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04299581RecruitingPhase 2
Freezing treatment plus immunotherapy for advanced bile-duct cancer
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
ShanghaiAges 18 years+ - NCT06852287RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct and gallbladder cancer
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
Tianjin, TiaAges 18 years+ - NCT06208462RecruitingPhase 2
Combination therapy before surgery for high-risk bile duct cancer
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
Nanjing, JiangsuAges 18–75 - NCT07260175RecruitingPhase 2
Ivosidenib maintenance for IDH1-mutated bile duct cancer
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
AachenAges 18 years+ - NCT07235007Recruiting
New treatment for bile duct cancer with heat, immunotherapy, and chemo
This trial tests a combination of heat therapy inside the bile duct (endobiliary RFA) with immunotherapy (durvalumab) and chemotherapy (gemcitabine and cisplatin) for people with unresectable extrahepatic cholangiocarcinoma. The goal is to see if adding the heat treatment improves outcomes.
AichiAges 18 years+
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangiocarcinoma?
- Yes. Clin2 currently lists 190 recruiting cholangiocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangiocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangiocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.